RTP Mobile Logo

Saturday, March 16, 2019, Honolulu, Hawaii, 11:00 AM – 12:30 PM

Data + Perspectives: Clinical Investigators Explore Emerging Research and Actual Patients with Uterine Sarcomas

An Independent CME Satellite Symposium During the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer

Event Details

Hawaii Convention Center
1801 Kalakaua Ave
Honolulu, HI 96815

10:30 AM – 11:00 AM — Registration
11:00 AM – 12:30 PM — Educational Lunch Meeting

Meeting Room:
Kalakaua Ballroom A (Level 4)

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Amanda Nickles Fader, MD
Associate Professor and Director
The Kelly Gynecologic Oncology Service
Director, Center for Rare Gynecologic Cancers
Johns Hopkins Medicine
Baltimore, Maryland

Mario M Leitao Jr, MD
Attending Surgeon and Member, Division of Gynecology
Professor, Weill Cornell Medical College
Director, Gynecologic Oncology Fellowship Program
Director, Minimal Access and Robotic Surgery Program
Department of Surgery
Memorial Sloan Kettering Cancer Center
New York, New York

Angeles Alvarez Secord, MD, MHSc
Professor, Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Brian A Van Tine, MD, PhD
Medical Oncology
Associate Professor of Medicine
Sarcoma Program Director
Washington University in St Louis
Siteman Cancer Center
St Louis, Missouri

Neil Love, MD
Research To Practice
Miami, Florida


This CME symposium will focus exclusively on the management of uterine and other gynecologic sarcomas.

Research To Practice president and medical oncologist Dr Neil Love will moderate the program and will be joined by an invited faculty panel of 4 clinical investigators specializing in the management of gynecologic sarcomas. The program will be divided into 4 modules, each featuring a blend of instructional case presentations from a faculty member’s practice, related panel discussion and a faculty member-led review of ongoing or recently published clinical research relevant to the clinical scenarios covered. To make the program more interactive and relevant, clinician attendees will use iPads® to complete a survey to provide their perspectives on the cases presented and other practical management issues. Survey results will be displayed throughout each module to illuminate any knowledge and practice gaps between the faculty and attending physicians. Attendees will also be encouraged to use the iPads to submit their own questions and cases to the faculty. Dr Love will incorporate select submissions into the panel discussions to foster additional conversation and ensure that a variety of perspectives emerge.

A detailed agenda will be made available in the coming weeks.

CE Information

Target Audience:
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Appreciate the importance of multidisciplinary collaboration in the diagnosis and management of gynecologic sarcomas, and use this knowledge to design a process to optimize tissue procurement, accurate histological assessment, tertiary care referral and treatment outcome.
  • Develop an evidence-based strategy for the treatment of Stage I to III uterine sarcoma, considering the potential contributions of surgery, radiation therapy and cytotoxic therapy.
  • Use guideline-endorsed monitoring protocols and techniques to effectively screen patients with localized uterine leiomyosarcoma (uLMS) for metastases.
  • Appraise available safety and efficacy data with targeted and cytotoxic therapies approved for the treatment of advanced gynecologic sarcomas, and consider how these agents can be optimally incorporated into clinical management algorithms.
  • Recognize the role PDGFRα (platelet-derived growth factor alpha) expression plays in tumor proliferation and growth, and consider this information in the selection of therapy for patients with advanced uLMS.
  • Develop an understanding of the mechanism of action, available efficacy and safety data and FDA-approved indication for olaratumab, and use this knowledge to appropriately integrate this novel agent into current clinical algorithms.
  • Recognize the toxicities and adverse events associated with novel agents used in the management of soft tissue sarcomas, and formulate strategies to minimize and manage these side effects.
  • Recall new data with other investigational agents demonstrating promising activity in patients with uterine and other gynecologic sarcomas, and discuss ongoing trial opportunities with eligible individuals.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by an educational grant from Lilly.


Hawaii Convention Center
1801 Kalakaua Ave
Honolulu, HI 96815

Meeting Room:
Kalakaua Ballroom A (Level 4)

The Hawaii Convention Center is the main venue for the SGO Annual Meeting on Women’s Cancer.



This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.